华东医药(000963) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥7,836,744,769.85, representing a 9.61% increase compared to ¥7,149,353,940.70 in the same period last year[7]. - Net profit attributable to shareholders was ¥659,198,384.27, up 21.17% from ¥544,014,117.67 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥656,213,602.52, reflecting a 22.94% increase from ¥533,772,576.37 in the previous year[7]. - The basic earnings per share increased to ¥0.6781, a rise of 21.18% compared to ¥0.5596 in the same period last year[7]. - The total profit for the period was CNY 846,992,984.69, compared to CNY 687,169,315.00 in the previous year, marking an increase of 23.3%[36]. - The company's operating profit for Q1 2018 was CNY 849,160,257.96, an increase of 24.5% from CNY 682,335,080.15 in Q1 2017[36]. - The company reported a total comprehensive income of CNY 690,784,749.20 for Q1 2018, compared to CNY 564,700,183.17 in Q1 2017, reflecting a growth of 22.4%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥17,347,933,943.17, an increase of 8.51% from ¥15,987,106,537.46 at the end of the previous year[7]. - The total liabilities increased to ¥7,848,286,273.14 in Q1 2018 from ¥7,178,243,616.64 in the previous year, representing a rise of 9.3%[29]. - The company's total equity reached ¥9,499,647,670.03, up from ¥8,808,862,920.82, marking an increase of 7.8% year-over-year[30]. - Cash and cash equivalents decreased by 35.51% to ¥1,615,536,212.03 due to cash outflows from operating activities[15]. - The ending balance of cash and cash equivalents was 1,569,343,776.74 CNY, down from 1,652,789,121.46 CNY, indicating a decrease of about 5.0%[44]. Cash Flow - The net cash flow from operating activities improved to -¥557,420,306.46, a 36.77% improvement from -¥881,508,811.65 in the same period last year[7]. - Total cash inflow from operating activities was 7,849,774,139.06 CNY, compared to 6,340,401,022.18 CNY in the same period last year, representing an increase of approximately 23.8%[43]. - Cash outflow from operating activities totaled 8,407,194,445.52 CNY, up from 7,221,909,833.83 CNY, reflecting a year-over-year increase of about 16.4%[43]. - The net cash flow from investing activities was -266,779,980.30 CNY, compared to -31,054,447.56 CNY in the previous year, indicating a significant increase in cash outflow[44]. - The net cash flow from financing activities improved by 227.20% to ¥17,525,439.01, mainly due to a decrease in short-term borrowings[16]. Shareholder Information - The company reported a total of 22,317 common shareholders at the end of the reporting period[11]. - The largest shareholder, China Yuanda Group Co., Ltd., held 41.77% of the shares, amounting to 406,076,754 shares[11]. Expenses - Total operating costs for Q1 2018 were ¥6,997,637,232.02, up from ¥6,485,213,239.76 in the previous year, reflecting a year-over-year increase of 7.9%[35]. - Management expenses increased by 44.76% to ¥245,778,216.08, mainly due to increased R&D expenses[15]. - The sales expenses for Q1 2018 were CNY 1,339,046,688.13, an increase of 18.8% compared to CNY 1,126,905,521.52 in Q1 2017[36]. - The tax expenses for the quarter amounted to CNY 156,208,235.49, up from CNY 122,469,131.83 in the previous year, indicating a rise of 27.5%[36]. Receivables and Inventory - Accounts receivable increased by 30.92% to ¥6,395,224,418.19, attributed to the expansion of sales scale[15]. - Other receivables rose by 129.36% to ¥106,058,064.32, mainly due to an increase in advance payments[15]. - Inventory levels slightly decreased to ¥1,714,719,818.67 from ¥1,756,699,036.26, a reduction of 2.4%[31].